High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette–Guerin therapy: A long-term survival analysis

Qu, Kai; Gu, Jian; Ye, Yuanqing; Williams, Stephen B.; Dinney, Colin P.; Wu, Xifeng; Kamat, Ashish M.

doi:10.1080/2162402x.2016.1265719

Cited by 21 publications

(11 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, CXCL10 was not included in this study. Although IL-8 was previously studied as a potential biomarker of responsiveness when released in the initial hours after instillation [18,19,20], our data show a decrease in this cytokine over time in responder patients. Based on our results, a focused study in a larger cohort is being planned in order to test this hypothesis and validate the use of CXCL10 as a biomarker for response.…”

Section: Discussioncontrasting

confidence: 58%

BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine

Ashiru

Esteso

García‐Cuesta

et al. 2019

Cancers

View full text Add to dashboard Cite

Background: Intra-vesical instillation of Bacille Calmette–Guérin (BCG), an attenuated strain of Mycobacterium bovis, is an effective therapy for high-grade non-muscle invasive bladder cancer (NMIBC), which provokes a local immune response resulting in 70% of patients free of relapse after three years. Because non-responder patients usually have a bad prognosis, the early identification of treatment failure is crucial. We hypothesized that, if an effective immune response was taking place in the bladder, soluble factors would be released to the urine many days after BCG instillations. Methods: An extensive panel of cytokines and chemokines released into the urine seven days after every BCG instillation was screened in a cohort of NMIBC patients over three years. Results: The determinations of the urinary concentrations of cytokines, chemokines, and creatinine showed that increasing concentrations of C-X-C motif chemokine 10 (CXCL10) also known as interferon-inducible protein 10 (IP10) could be detected during the six-week induction cycle of BCG-treated patients released into the urine by CD14+ cells. In vitro, CXCL10 facilitated the recruitment of effector immune cells after the BCG-mediated upregulation of CXCR3 in both T- and natural killer (NK)-cells. Conclusions: The high concentrations of chemokine detected one week after the encounter with mycobacteria suggest that the CXCL10 axis might be related to the intensity of the immune anti-tumor response.

show abstract

Section: Discussioncontrasting

confidence: 58%

BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine

Ashiru

Esteso

García‐Cuesta

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Therefore, European Association of Urology (EAU) Guidelines on NMIBC recommend intravesical BCG immunotherapy after TURBT in patients with intermediate-or high-risk NMIBC (1). Some studies have investigated the effect of intravesical BCG immunotherapy on some angiogenetic factors and cytokines such as interleukin (IL)-8 in patients with NMIBC (6,7). They suggested that these factors and cytokines might be used for the follow up after intravesical BCG immunotherapy in NMIBC.…”

Section: Resultsmentioning

confidence: 99%

The Effect of Treatment on Cytokine Levels in Non Muscle Invasive Bladder Cancer

Ucer¹,

Temeltaş²,

Müezzinoğlu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Objectives The aim of the present study was to investigate the effect of treatment on IL-1, IL-6, IL-8 and neopterin levels in patients with non-muscle invasive bladder cancer (NMIBC). Methods Thirty patients with NMIBC and 30 age-matched controls were included in the study. Preoperative, postoperative first control (at two weeks after second transurethral resection of bladder tumor (TURBT)) and second control (at the end of intravesical immunotherapy) blood samples were analyzed by ELISA to determine IL-1, IL-6, IL-8 and neopterin levels. The mean cytokine levels of the patients were statistically compared as well as comparing the patients’ and controls’ levels. Results There were no statistically significant differences between the mean IL-1, IL-6, IL-8 and neopterin levels of the patient and control group before initial TURBT. In the patient group, there were no statistically significant differences in the IL-6 and IL-8 levels after both TURBT and intravesical BCG therapy. The mean of preoperative IL-1 and neopterin levels significantly decrease after TURBT (p<0.05=). However this reduction do not continue after intravesical BCG instillations. Conclusions The finding of this study showed that the IL-1, IL-6, IL-8 and neopterin levels of the patients with NMIBC were similar to the levels of healthy controls. The IL-1 and neopterin levels significantly decreased after TURBT. But this reductions did not continue after intravesical BCG instillation. These findings demonstrate that IL-1 and neopterin levels decrease after TURBT due to the reduction of tumor weight or tumor removal.

show abstract

“…Cytokines and chemokines have already been shown to be suitable for the detection and prediction of the BCG response. 12 Previous studies have developed multiple cytokine panels to predict the treatment response to BCG; however, they have limited clinical usefulness for the measurement techniques and costs . 4,13 In an attempt to identify a robust predictive biomarker for potential clinical use, we evaluated 48 cytokines and chemokines involved in several stages of the mechanism of BCG immunotherapy and screened the cytokine or chemokine with most predictive value.…”

Section: Discussionmentioning

confidence: 99%

Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer

Zhong

Wang

et al. 2020

OncoImmunology

View full text Add to dashboard Cite

The prediction of the response to Bacillus Calmette-Guerin (BCG) can help identify non-muscle-invasive bladder cancer (NMIBC) patients that may be better served with alternative therapy. Several cytokine profiles present promising results, but they are difficult to use in clinical practice. In this prospective, longitudinal study, we tried to identify reliable serum cytokines/chemokines to predict the response to BCG using samples collected before and during BCG induction therapy. We used the Bio-plex multiplex assays to identify potential BCG failure-related serum cytokines/chemokines in the discovery set (n = 13). After screening, we identified CCL27 as the top candidate biomarker for predicting the response to BCG (P = .003). In the validation set, we found that the AUC of the baseline CCL27 was 0.730 (95% CI 0.515-0.945, P = .040) along with 67% sensitivity, 78% specificity. The changes from baseline to last timepoint can also distinguish BCG responders from non-responders (AUC: 0.726, 95% CI 0.474-0.979, P = .044). Moreover, the combination score of serum CCL27 (CS CCL27), based on the baseline and changes of CCL27, could further improve the predictive accuracy with an AUC of 0.897 (95% CI 0.790-1.000, P < .001). The correlations between CCL27 and local/systemic immunologic parameters were further analyzed. The level of serum CCL27 was strongly correlated with regulatory T cells (Tregs) in the tumor microenvironment (P = .002), indicating that CCL27 may promote the recruitment of Tregs into the tumor microenvironment. Our results show that serum CCL27 may represent a practical and reliable marker for the prediction of the response to BCG in NMIBC.

show abstract

High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette–Guerin therapy: A long-term survival analysis

Abstract: (2017) High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis, OncoImmunology, 6:2, e1265719,

Cited by 21 publications

References 36 publications

BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine

BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine

The Effect of Treatment on Cytokine Levels in Non Muscle Invasive Bladder Cancer

Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer

Contact Info

Product

Resources

About